$NTRA

RABINOWITZ DANIEL sold $485K of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 1,887 shares of Natera, Inc. (NTRA) at an average of $257.08 ($254.07–$260.49, $0.49M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Jul 30, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not change Natera’s business outlook based on the information provided.

02

Market read

Insider selling under a 10b5-1 plan is generally low-signal; any trading impact is likely limited unless corroborated by other negative catalysts.

03

What to watch

Traders should check whether there were concurrent insider buys/sales by other executives and whether the sale size is unusual relative to prior Form 4 activity.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-29, covering sales on 2026-07-27 to 2026-07-28.

Background

The article is a primary-source SEC Form 4 insider transaction for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera Form 4 shows Daniel Rabinowitz, Chief Legal Officer, sold 1,887 shares in open-market trades under a 10b5-1 plan at $254.07 to $260.49.

Expected impact

Likely limited, short-lived impact unless paired with other negative company news.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale by an officer; it does not provide new operational, financial, or regulatory information.

Market effects

Minimal; insider sale in a single biotech/health-tech name does not reset sector fundamentals.

Minimal; US-listed filing with no broader macro/regional catalyst.

Minimal; no international transaction or regulatory action described.

Counterpoint

Because the trades are explicitly under a pre-arranged 10b5-1 plan, the sale may reflect diversification or liquidity needs rather than a bearish view.

Key entities

  • Natera, Inc.

    US-listed company whose officer insider sale is disclosed via SEC Form 4.

  • Daniel Rabinowitz

    Chief Legal Officer who sold shares in open-market transactions under a 10b5-1 plan.

Related articles

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.